- Home
- ZVSA
ZVSA
ZyVersa Therapeutics Inc.
as 04-24-2025 4:00pm EST
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $6.70 | Next Earning Date: | 05-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZyVersa Therapeutics Inc. News
ZVSA Breaking Stock News: Dive into ZVSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 hours ago
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
Insider Monkey
14 days ago
Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday?
GlobeNewswire
16 days ago
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire
a month ago
ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
a month ago
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
GlobeNewswire
a month ago
ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer’s Disease Mouse Model
GlobeNewswire
2 months ago
ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market
GlobeNewswire
2 months ago
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
Compare ZVSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVSA ZyVersa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.